Targacept Reports Results of Pain Trial

Targacept’s TC-2696, a candidate for pain relief following third-molar extraction surgery, did not meet its primary endpoint of superior pain relief four or six hours after dosing compared with placebo in a Phase II trial.

In preclinical studies, TC-2696 demonstrated analgesic activity in acute, chronic and inflammatory nociceptive pain and neuropathic pain, Targacept said.

The company will analyze data from the trial and consider TC-2696’s development with partner GlaxoSmithKline.